News

GoGo squeeZ adds ApplePear flavor to line of squeezable applesauces

BY Jason Owen

NEW YORK — GoGo squeeZ on Tuesday announced the newest addition to its line of squeezable applesauce pouches: ApplePear.

The new flavor is being introduced on the heels of the company’s family-oriented, "Wherever you go, go playfully" campaign, which is dedicated to providing tools for families to "empower playfulness," as well as a donation portion where GoGo squeeZ will donate $1 — up to $100,000 — to The Life is good Playmakers, an organization that aims to help children overcome poverty, violence and illness through the power of play, for every share of the company’s #GoGoPlayfully hashtag or other website multimedia content.

Like the other flavors, the new ApplePear option provides the same benefits as the company’s other products: easy mobility in a resealable, BPA-free pouch featuring a built-in straw; all-natural 100% fruit, gluten-free, dairy-free, nut-free, and made with no artificial flavors or preservatives; each pouch contains only 60 calories.

GoGo squeeZ is available at major retailers nationwide, including Walmart, Target, Costco, Kroger and Whole Foods Market, for a suggested retail price of $2.99 per four-pack.


Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

District court dismisses Teva case against Mylan over four patents on Copaxone

BY Alaric DeArment

PITTSBURGH — A federal court in New York has dismissed a lawsuit alleging that Mylan infringed four of Teva Pharmaceutical Industries’ patents when it sought Food and Drug Administration approval for a multiple sclerosis drug.

Mylan had filed with the FDA for approval of a generic version of Teva’s Copaxone (glatiramer acetate), attracting a patent-infringement suit from Teva alleging that it violated four patents on the drug, according to FDA records. The U.S. District Court for the Southern District of New York has dismissed the case.

Mylan said it would appeal to the Federal Circuit a separate decision at the same district court by a different judge that upheld nine other patents.


Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Return of venerable McNeil, Novartis brands will make Q4 highly promotional

BY Michael Johnsen

NEW BRUNSWICK, N.J. — Johnson & Johnson will be making a strong comeback across its portfolio of McNeil Consumer Healthcare recalled OTC products in the fourth quarter of this year. And with a J&J pledge to partner with key retail partners "on strategic relationships that are rebuilding our relationships and supporting their health and wellness strategies," this fourth quarter will likely be more promotional all around. 

"By year end, our plan is to deliver reliable and consistent supply of three quarters of the product brands," Sandra Peterson, group worldwide chairman, told analysts during a quarterly conference call Tuesday. "In the first half of 2013, we achieved the U.S. OTC operational growth of 19.7%, which includes 26% growth in revenues in over-the-counter medicines, and we are winning the hearts of consumers as these products return to the shelves in all four segments: cough, cold and flu; allergy; pain; and digestive health," she said. 

But even with that immediate success behind them, J&J will be investing heavily going forward. "In addition to all of the remediation efforts, we also are going to ensure that we are investing sufficiently to bring these brands back and bring them back fully to consumers and retailers," Peterson said. "Our current estimation is that we will probably be spending at a higher rate than our historical averages as we are bringing all of these brands back," she said. "Clearly, our intent and our desire is to get back to the share numbers that we had before we went in to the [Consent Decree] process and that’s what we are really focused on doing."

As J&J ramps up marketing and merchandising commitments for the fourth quarter, competitors are expected to follow suit. Especially Novartis, which, like J&J is bringing several venerable OTC brands back into the fold following a recall. "The combination of J&J and Novartis coming back at the same time, you’ll have those companies … doing more merchandising, advertising and promotion," commented Laura Mahecha, industry manager at Kline’s Healthcare practice. "The competitive set will match them [so as to] not get lost in [the] noise," she said. For an upcoming cough/cold season that will be compared against an extremely strong season a year ago, that suggests there will be a significant amount of spending in this category this fall irrelevant of sickness trends. 


Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES